Global Patent Index - EP 1343501 A4

EP 1343501 A4 2004-12-15 - THERAPY FOR HERPES NEUROLOGICAL VIRAL CONDITIONS UTILIZING 1,4-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS

Title (en)

THERAPY FOR HERPES NEUROLOGICAL VIRAL CONDITIONS UTILIZING 1,4-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS

Title (de)

THERAPIE FÜR NEUROLOGISCHE INFEKTIONEN MIT DEM HERPES-VIRUS UNTER VERWENDUNG VON 1,4-DIHYDROPYRIDIN-KALZIUMANTAGONISTEN

Title (fr)

UTILISATION DE BLOQUEURS DU CANAL CALCIUM A LA 1,4-DIHYDROPYRIDINE POUR TRAITER DES ATTEINTES NEUROLOGIQUES IMPUTABLES AU VIRUS DE L'HERPES

Publication

EP 1343501 A4 (EN)

Application

EP 00987986 A

Priority

US 0031994 W

Abstract (en)

[origin: WO0241893A1] A therapy for Bell's Palsy in mammals is proposed that rests on a causal hypothesis involving both endothelin and the herpes virus, particularly the herpes simplex virus for Bell's Palsy. Similarly, the same therapy would apply to Ramsay Hunt, but in this case the herpes zoster virus would be involved in the causal hypothesis. Other herpes viral related conditions are also suggested to be amenable such as herpes simplex encephalitis. The therapy uses therapeutically effective doses of calcium channel blockers that are of the 1,4-dihydropyridine derivative class, such as felodipine but also including nifedidine, nimodipine, nisodipine or alenodipine. The treatment is proposed as continuing up to the tenth day of progression, but to be started as early as possible. Acyclovir or other herpes antagonists such as famciclovir may also be administered in therapeutically effective dosages.

IPC 1-7 (main, further and additional classification)

A61K 31/44; A61K 31/435; A61K 31/445; A61K 31/495; A61K 31/50; A61K 31/52

IPC 8 full level (invention and additional information)

A61K 45/00 (2006.01); A61K 31/435 (2006.01); A61K 31/44 (2006.01); A61K 31/4422 (2006.01); A61K 31/445 (2006.01); A61K 31/495 (2006.01); A61K 31/50 (2006.01); A61K 31/52 (2006.01); A61K 31/522 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 31/12 (2006.01)

CPC (invention and additional information)

A61K 31/445 (2013.01); A61K 31/435 (2013.01); A61K 31/44 (2013.01); A61K 31/495 (2013.01); A61K 31/50 (2013.01); A61K 31/52 (2013.01)

Citation (search report)

  • [A] US 5039678 A 19910813 - HUTCHINS PHILLIP M [US]
  • [A] WO 9414441 A1 19940707 - ASTRA AB [SE]
  • [A] LUITEN P G M ET AL: "Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca<2+> antagonist nimodipine, influence of aging and developmental drug treatment", NEURODEGENERATION, ACADEMIC PRESS LTD., LONDON, GB, vol. 4, no. 3, September 1995 (1995-09-01), pages 307 - 314, XP004552087, ISSN: 1055-8330
  • See also references of WO 0241893A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

EPO simple patent family

WO 0241893 A1 20020530; AU 2425001 A 20020603; CN 1479616 A 20040303; EP 1343501 A1 20030917; EP 1343501 A4 20041215; JP 2004513965 A 20040513; NO 20032276 A 20030630; NO 20032276 D0 20030520

INPADOC legal status


2006-12-06 [18D] APPLICATION DEEMED TO BE WITHDRAWN

- Effective date: 20060531

2004-12-15 [A4] DESPATCH OF SUPPLEMENTARY SEARCH REPORT

- Effective date: 20041104

2003-09-17 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20030623

2003-09-17 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

2003-09-17 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO:

- Countries: AL LT LV MK RO SI